drugset / Trial / NCT07519226
Effectiveness and Safety of Penehyclidine Hydrochloride for Improving Microcirculatory Dysfunction in Critically Ill Children
RandomizedParallel-groupOpen-labelTreatment
Summary
This prospective randomized controlled trial was designed to evaluate whether the M1/M3-selective antagonist penehyclidine hydrochloride could more effectively reverse pediatric microcirculatory dysfunction than traditional atropine, particularly when macrohemodynamics appear normalized.
Timeline
- Start
- 2024-05-08
- Primary completion
- 2026-03-01
- Completion
- 2026-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Atropine | Other / unclassified | — | — |
| Subject | Penehyclidine | Small molecule | — | — |
Indications
No indication recorded.